Business News • PR NewsWire • Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR®

Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR®

Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR®

BERLIN, May 30 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and di

View More : http://www.prnewswire.com/news-releases/phase-2-clinical-trial-data-show-significant-improvements-in-outcomes-and-sympto...

Releted News by prnewswire

U.S. Census Bureau Daily Feature for May 30

Rentrak Announces Box Office Numbers for Weekend of May 28, 2010

U.S. Census Bureau Daily Feature for May 31

Flextronics to Open New Power Facility in Ganzhou, Jiangxi China